"Prescription of a THC/CBD-Based Medication to Patients with Dementia: A Pilot Study in Geneva"

Dementia is characterized by a deterioration in memory, thinking, behavior, and autonomy in daily life activities. 

According to the World Health Organization, there were around 50 million persons worldwide suffering from dementia and this number is increasing with the global aging of the population in most countries. 

Currently, the options for treating BPSD (Behavioral and Psychological Symptoms of Dementia) include pharmacological and nonpharmacological therapies. Psychotropic medications are often used to reduce the frequency and severity of BPSD, but in the majority of patients, they provide only modest symptom control and important side effects.

The interest of cannabinoids in Alzheimer disease and other forms of dementia has increased first as neuroprotective drugs in animal studies. Indeed, some studies suggest a potential beneficial effect of CB1 and CB2 receptor agonists on reducing harmful β-amyloid peptide action and tau phosphorylation seen in Alzhei­mer disease as well as increasing intrinsic brain repair mechanisms.

"Cannabis & Alzheimer's Desease"

Alzheimer's disease (AD) is a neurological disorder of unknown origin that is characterized by a progressive loss of memory and learned behavior. For both patients and their loved ones, Alzheimer’s Disease ranks among the most challenging conditions one can experience.

This chronic neurodegenerative disorder leads to progressive symptoms including dementia, memory loss, emotional issues, and speech problems, among others. Few treatments exist and available therapies only address some symptoms, but not the progression of the disease itself.

The search for new therapeutic options has led to significant interest in cannabis-based treatments and researchers are currently working to advance our understanding of the possible roles medical cannabis could play in the future of Alzheimer’s treatment.

Preclinical data shows the potential of cannabinoids to moderate the progression of AD while clinical data demonstrates that these compounds can provide symptom relief, but lets take a look in what 10 studies says about it...

"Using CBD to Treat the Symptoms of Alzheimer’s & Other Forms of Dementia"

Worldwide, 50 million people are living with Alzheimer's and other dementias.

Alzheimer’s disease is a degenerative brain disease and the most common form of dementia. 

Dementia its an overall term that describes a group of symptoms.

Dementia is a general term for loss of memory, language, problem-solving and other thinking abilities that are severe enough to interfere with daily life. Alzheimer's is the most common cause of dementia.

The dementia-related conditions that can be helped by CBD include: Alzheimer’s disease, Vascular Dementia, Dementia with Lewy bodies (DLB), Parkinson’s disease, Frontotemporal dementia and Huntington’s disease.

According to researchers at California’s Salk Institute, their 2017 study has found evidence that cannabinoids such as CBD could help remove dementia from, and increase connections between, brain cells. Those results were validated by other laboratories. 

There are three ways CBD can work to improve health outcomes for persons with dementia: by reducing inflammation, by reducing oxygen buildup, and by working as a brain stimulant and neuroprotectant. From a user’s perspective, CBD may reduce stress and anxiety in the individual with dementia as well as reduce the decline of memory and other brain functions.

"Evidence for Therapeutic Properties of CBD/THC in Alzheimer's Disease"

Alzheimer's Disease (AD) is a debilitating neurodegenerative disease that is characterized by cognitive decline.

It is the most common form of dementia,accounting for over 60% of cases and affecting over 33 million people worldwide.


Unfortunately the current approved AD treatments only provide limited therapeutic benefits.

There are four approved drugs available, but unfortunately, all of them have been associated with adverse effects. Acetylcholinesterase inhibitors may cause nausea, vomiting, diarrhea and weight loss, while memantine is known to cause hallucinations, dizziness and fatigue.Furthermore, none of these treatments prevent or reverse the progression of the disease but rather they treat the disease symptoms with limited efficacy

Cannabidiol (CBD) is a non-psychoactive phytocannabinoid that has demonstrated neuroprotective, anti-inflammatory and antioxidant properties. It is investigated as a potential multifunctional treatment option for AD.

Here, we summarize the current status quo of effects of CBD in established pharmacological and transgenic animal models for AD.The phytocannabinoid cannabidiol (CBD) is a prime candidate for this new treatment strategy.

The in vivo therapeutic potential of CBD in AD has not been widely documented, however, there are a number of studies that have reported the effect of CBD in pharmacological models of AD. These studies have described anti-inflammatory and neuroprotective effects of CBD.